Watchlist · 67/100Apr 22, 11:00 AM EDT
Moderna Launches Phase 3 Trial for mRNA-Based Bird Flu Vaccine
MRNA
Moderna (MRNA) has commenced patient dosing in a Phase 3 clinical trial for its bird flu vaccine candidate, mRNA-1018, in both the U.S. and U.K. This trial, which is supported by funding, represents a significant step in the development of a vaccine targeting…
- ▹Phase 3 trial initiation indicates regulatory progress.
- ▹Strong technology platform with mRNA expertise, but single asset limits commercial potential.
Neutral · 59/100Apr 22, 12:27 PM EDT
AbbVie Unveils $1.4 Billion Manufacturing Facility in North Carolina
ABBV
AbbVie (ABBV) has revealed plans to invest $1.4 billion in a new 185-acre pharmaceutical manufacturing campus in Durham, North Carolina, representing its inaugural major investment in the state. This strategic move is expected to enhance AbbVie's production ca…
- ▹New manufacturing campus indicates commitment to capacity expansion.
- ▹No immediate regulatory or commercial concerns noted.
High Risk · 10/100Apr 22, 1:37 PM EDT
CDC Journal Prevents Publication of Key COVID Vaccine Findings
MRNAPFE
A significant report detailing the impact of COVID-19 vaccines on reducing hospital visits has been halted from publication in the CDC's Morbidity and Mortality Weekly Report, despite passing scientific review. This development raises concerns for investors in…
- ▹FDA warning/rejection controversy due to blocked publication
- ▹No positive regulatory or commercial developments